Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Net Margin (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Net Margin for 15 consecutive years, with 11.81% as the latest value for Q3 2025.

  • On a quarterly basis, Net Margin rose 740.0% to 11.81% in Q3 2025 year-over-year; TTM through Sep 2025 was 6.2%, a 7238.0% increase, with the full-year FY2024 number at 11.43%, up 8677.0% from a year prior.
  • Net Margin was 11.81% for Q3 2025 at Gyre Therapeutics, up from 1.65% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 27.72% in Q1 2024 to a low of 1830.73% in Q1 2022.
  • A 5-year average of 430.34% and a median of 0.36% in 2024 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: plummeted -150475bps in 2021, then soared 183973bps in 2023.
  • Gyre Therapeutics' Net Margin stood at 848.75% in 2021, then surged by 97bps to 29.47% in 2022, then tumbled by -921bps to 300.91% in 2023, then skyrocketed by 100bps to 0.36% in 2024, then surged by 3425bps to 11.81% in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Net Margin are 11.81% (Q3 2025), 1.65% (Q2 2025), and 12.23% (Q1 2025).